JP2023535034A - 5-メチル-1,2,4-オキサジアゾール-3-イル化合物の低用量レジメン及び製剤化 - Google Patents
5-メチル-1,2,4-オキサジアゾール-3-イル化合物の低用量レジメン及び製剤化 Download PDFInfo
- Publication number
- JP2023535034A JP2023535034A JP2023504346A JP2023504346A JP2023535034A JP 2023535034 A JP2023535034 A JP 2023535034A JP 2023504346 A JP2023504346 A JP 2023504346A JP 2023504346 A JP2023504346 A JP 2023504346A JP 2023535034 A JP2023535034 A JP 2023535034A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- day
- total dose
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| US63/055,362 | 2020-07-23 | ||
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535034A true JP2023535034A (ja) | 2023-08-15 |
| JP2023535034A5 JP2023535034A5 (cg-RX-API-DMAC7.html) | 2024-07-24 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504346A Pending JP2023535034A (ja) | 2020-07-23 | 2021-07-23 | 5-メチル-1,2,4-オキサジアゾール-3-イル化合物の低用量レジメン及び製剤化 |
Country Status (21)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014331A1 (zh) * | 2016-07-22 | 2018-01-25 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5-甲基-1,2,4-二唑-3-基化合物 |
| EP3829634A1 (en) * | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko not_active Withdrawn
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014331A1 (zh) * | 2016-07-22 | 2018-01-25 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000194A1 (es) | 2023-07-21 |
| EP4185291C0 (en) | 2025-07-09 |
| CA3186808A1 (en) | 2022-01-27 |
| AU2021312894B2 (en) | 2025-09-11 |
| PE20231031A1 (es) | 2023-07-10 |
| IL300023A (en) | 2023-03-01 |
| BR112023000975A2 (pt) | 2023-02-07 |
| KR20230043905A (ko) | 2023-03-31 |
| CN116323604A (zh) | 2023-06-23 |
| ES3039536T3 (en) | 2025-10-22 |
| ECSP23005057A (es) | 2023-02-28 |
| AR123031A1 (es) | 2022-10-26 |
| MX2023000993A (es) | 2023-03-01 |
| PH12023550177A1 (en) | 2024-03-18 |
| AU2021312894A1 (en) | 2023-02-23 |
| EP4185291A1 (en) | 2023-05-31 |
| US20230338349A1 (en) | 2023-10-26 |
| JOP20230018A1 (ar) | 2023-01-23 |
| DOP2023000009A (es) | 2023-02-15 |
| CO2023000594A2 (es) | 2023-01-26 |
| WO2022020663A1 (en) | 2022-01-27 |
| EP4185291B1 (en) | 2025-07-09 |
| TW202220650A (zh) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120157472A1 (en) | Method for treating colorectal cancer | |
| US12427142B2 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| JP2017061482A (ja) | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 | |
| HK1226940A1 (zh) | 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症 | |
| BR112013005907B1 (pt) | Composição farmacêutica parenteral | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| KR20050044587A (ko) | B형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도 | |
| WO2022177428A1 (en) | Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia | |
| CA3100792A1 (en) | Methods and compositions for treatment of alzheimer's disease | |
| EP2670405B1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| RU2268725C2 (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств | |
| JP7068222B2 (ja) | 高純度治療用骨剤 | |
| EP4185291B1 (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| JPH0251885B2 (cg-RX-API-DMAC7.html) | ||
| HK40084518B (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| HK40084518A (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| JP6420923B1 (ja) | 医薬 | |
| EP4364742A1 (en) | Pharmaceutical composition for treating solid tumors | |
| RU2345775C1 (ru) | Нестероидное противовоспалительное лекарственное средство | |
| AU2005224154A1 (en) | Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition | |
| Miljković et al. | P. 1.124 Does amitriptyline influence plasma concentrations of fluvoxamine in patients on combined therapy? | |
| Timotijevic et al. | P. 1.123 Combination of amitriptyline and fluvoxamine with lithium-carbonate in the treatment of major depressive disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240716 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250930 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260407 |